Danaher Co. (NYSE:DHR) Shares Acquired by Dakota Wealth Management

Dakota Wealth Management lifted its holdings in Danaher Co. (NYSE:DHR) by 1.0% in the third quarter, Holdings Channel reports. The firm owned 8,161 shares of the conglomerate’s stock after buying an additional 82 shares during the period. Dakota Wealth Management’s holdings in Danaher were worth $2,269,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the 1st quarter worth $30,000. MFA Wealth Advisors LLC acquired a new stake in Danaher during the 2nd quarter worth about $51,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher during the 2nd quarter valued at about $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

NYSE:DHR opened at $245.39 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $181.76 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a fifty day moving average of $269.52 and a two-hundred day moving average of $260.42.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the firm earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Analysts Set New Price Targets

DHR has been the subject of a number of research reports. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Leerink Partners upped their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Bank of America raised their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. The Goldman Sachs Group upped their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.